Cardiac Safety Assessment Assay Services

The cardiac safety assessment assays are available for preclinical evaluation of the safety of compounds to identify toxic drugs potentially inducing fatal cardiac tachyarrhythmia.

Ion channels are a diverse class of membrane proteins that play important roles in physiology. Deficits or the increase of ion channel activity caused by the activity of pharmacological agents are linked to several disease conditions. The inhibition of cardiac ion channels is linked to the generation of life-threatening arrhythmias. Therefore it is important to screen compounds against these channels to assess potential cardiac liability.

Screening options include:

Cell-based Assay Core Panel

Testing the core panel is a reasonable first step for assessment of cardiac safety of a new drug. Testing whether  a drug blocks ion channels hERG, Cav1.2 and Nav1.5 will help with go/no-go decisions early in the drug discovery process.
 

Target Category Data
hERG Potassium Channel Data sheet
Cav1.2 Calcium Channel Data sheet
Nav1.5 Sodium Channel Data sheet

Advanced Cardiac Safety Assessment

Via our collaborator PharmaCore Labs (PCL) Co., Ltd we offer ion channel cardiac assessment according to CiPA (Comprehensive in vitro Proarrhythmia Assay) guidelines for standardized procedures necessary for regulatory decision-making to advance drug development programs.

Testing of drug-induced action potential prolongation and changes in the QT interval help evaluate the side effects of new drug candidates to ensure cardiac safety.